Articles where Melior, or our drug discovery approach, was featured.

Integrated Platform Drug Discovery and Development Companies – Part 2: comparative analysis

By Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr

Drug Discovery World, Spring 2019

This paper favorably features Melior Discovery’s business model.

Read Full Article

Cell and Small Animal Models of Phenotypic
Drug Discovery

By Mihaly Szabo, Sara Svensson sjärvi, Ankur Saxena, Jianping Liu,
Gayathri Chandrasekar, Satish S. Kitambi

Drug Design, Development & Theory, June 2017

The phenotype-based drug discovery (PDD) approach is re-emerging as an alternative platform for drug discovery.

Read Full Article

Therapeutic Drug Repurposing, Repositioning and Rescue Part II: Business Review
By Dr Stephen Naylor, David M. Kauppi & Judge M. Schonfeld
Drug Discovery World, Spring 2015

There is an emerging consensus that the impact of Drug Repurposing, Repositioning and Rescue (DRPx) on the pharmaceutical industry is real and sustainable.

Read Full Article
Download PDF reproduced with kind permission of Drug Discovery World

Lazarus Drugs
By Kate Yandell
The Scientist, February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.

Read Full Article

Therapeutic Drug Repurposing, Repositioning and Rescue Part I: Overview
By Dr Stephen Naylor and Judge M. Schonfeld
Drug Discovery World, Winter 2014

The pharmaceutical industry is still beleaguered by escalating costs, stagnant productivity and protracted timelines as it struggles to bring therapeutic drugs to market.

Read Full Article
Download PDF reproduced with kind permission of Drug Discovery World

How were new medicines discovered?
By David C. Swinney & Jason Anthony
Nature Reviews Drug Discovery, July 2011

This seminal paper documents the superior pharmaceutical discovery productivity that has been achieved using phenotypic screening versus target-based drug discovery

Read Full Article

A Forensic Analysis of Drug Targets From 2000 Through 2012
By B. Munos
Clinical Pharmacology & Therapeutics June 2013

Pharmaceutical innovation is often measured by counting the new drugs approved by regulators. It is a simple and useful metric, but it has shortcomings. One of them is that it says little about the drugs’ innovativeness. […]

Read Full Article

Exploiting Complexity and the Robustness of Network Architecture for Drug Discovery
By Marc K. Hellerstein
JPET, January 2008

The issue of complexity stands at the center of contemporary drug discovery and development. The central problem in drug development today is attrition of drug candidates identified by the modern molecular target-based discovery approach […]

Read Full Article

Christopher Lipinski, PhD Named in Top Ten Most Influential People in Pharma
World Pharmaceutical Frontiers 2007 Edition Pharma 40

The Pharma 40 has been a great opportunity to evaluate the figures who have the bigest impact on our industry – an to see the sheer scope of their different influences. But when the votes came in, we had to triple-check our figures – not just for accuracy, but because the top spot was such a surprise […]

Read Full Article